/
Bristol-Myers Squibb Company ("we", the "Company", "Bristol Myers Squibb", or "BMS") was incorporated under the laws of the State of Delaware in August 1933 under the name Bristol-Myers Company, as successor to a New York business started in 1887. In 1989, Bristol-Myers Company changed its name to Bristol-Myers Squibb Company as a result of a merger.
$57.18
+$0.27 (+0.47%)
Price from 5 days ago
19.36% operating margin is respectable but not wide. ROIC at 10.30%. Suggests the business covers its cost of capital, but doesn't point to a wide moat.
Revenue declined 0.2% YoY. The question is whether this is cyclical or a structural shift.
Even for strong businesses, today's 16x P/E means the stock needs to keep delivering. There's no margin of safety if growth disappoints.
16.0x earnings, 9.8x FCF. Valuation is in a reasonable range. The main question is whether the business can re-accelerate or if current trajectory is already priced in.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$48.48B
▼ -0.2% YoY
Net Income (TTM)
$7.28B
▲ +178.8% YoY
Op. Margin
19.79%
▲ +36.7pp YoY
ROIC
10.29%
▲ +19.6pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$11.91B
▼ -7.9% YoY
Op. Cash Flow (TTM)
$13.31B
▼ -6.8% YoY
Net Debt
$37.93B
Cash & Equiv.
$10.49B
5Y CAGR: +2.5%
5Y CAGR: -0.7%
Continue Research